Lotze MT - Search Results

1

Clinical effects and toxicity of interleukin-2 in patients with cancer.

Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA. Lotze MT, et al. Cancer. 1986 Dec 15;58(12):2764-72. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z. Cancer. 1986. PMID: 3490903

2

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.

Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR. Marincola FM, et al. Among authors: lotze mt. Cancer Res. 1992 Dec 1;52(23):6561-6. Cancer Res. 1992. PMID: 1423301

3

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.

Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, Yang JC, Rosenberg SA. Lange JR, et al. Among authors: lotze mt. J Immunother (1991). 1992 Nov;12(4):265-71. doi: 10.1097/00002371-199211000-00007. J Immunother (1991). 1992. PMID: 1477077 Clinical Trial.

4

Delayed reactions to contrast media after interleukin-2 immunotherapy.

Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Choyke PL, et al. Among authors: lotze mt. Radiology. 1992 Apr;183(1):111-4. doi: 10.1148/radiology.183.1.1549655. Radiology. 1992. PMID: 1549655

5

Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.

Kasid A, Director EP, Stovroff MC, Lotze MT, Rosenberg SA. Kasid A, et al. Among authors: lotze mt. Cancer Res. 1990 Aug 15;50(16):5072-6. Cancer Res. 1990. PMID: 1696166

6

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Aebersold P, et al. J Natl Cancer Inst. 1991 Jul 3;83(13):932-7. doi: 10.1093/jnci/83.13.932. J Natl Cancer Inst. 1991. PMID: 2067036 Clinical Trial.

7

Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.

Wiebke EA, Custer MC, Rosenberg SA, Lotze MT. Wiebke EA, et al. Among authors: lotze mt. J Biol Response Mod. 1990 Apr;9(2):113-26. J Biol Response Mod. 1990. PMID: 2111373

8

IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.

Jablons D, Bolton E, Mertins S, Rubin M, Pizzo P, Rosenberg SA, Lotze MT. Jablons D, et al. Among authors: lotze mt. J Immunol. 1990 May 1;144(9):3630-6. J Immunol. 1990. PMID: 2158514

9

Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.

Lotze MT, Custer MC, Bolton ES, Wiebke EA, Kawakami Y, Rosenberg SA. Lotze MT, et al. Hum Immunol. 1990 Jun;28(2):198-207. doi: 10.1016/0198-8859(90)90020-p. Hum Immunol. 1990. PMID: 2190952 Review.

10

Changes in laboratory results for cancer patients treated with interleukin-2.

Huang CM, Elin RJ, Ruddel M, Sliva C, Lotze MT, Rosenberg SA. Huang CM, et al. Among authors: lotze mt. Clin Chem. 1990 Mar;36(3):431-4. Clin Chem. 1990. PMID: 2311209

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

573 results

Search Page

Filters